{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,6]],"date-time":"2025-06-06T04:05:40Z","timestamp":1749182740938,"version":"3.41.0"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,6,4]],"date-time":"2025-06-04T00:00:00Z","timestamp":1748995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,6,4]],"date-time":"2025-06-04T00:00:00Z","timestamp":1748995200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>The benefit of regional nodal irradiation (RNI) following modern primary systemic therapy (PST) in HER2-positive breast cancer (HER2\u2009+\u2009BC) remains under investigation. The current study evaluates RNI practice patterns and outcomes based on the pathological response to PST in clinically node-positive (cN+) HER2\u2009+\u2009BC.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>TRYPHAENA and NeoSphere are two randomized phase II trials that investigated PST for HER2\u2009+\u2009BC. The current study is a pooled analysis of both trials, focusing on cN\u2009+\u2009patients treated with HER2-targeted PST followed by breast-conserving surgery. The primary goal is to describe patterns of RNI practicein this population and its impact on breast cancer recurrence-free survival (BCRFS) and loco-regional recurrence-free survival (LRRFS).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Our analysis included a total of 90 patients with cN\u2009+\u2009disease. Complete nodal pathological response was achieved in 53 patients (58.9%). Patients with ypN0 had a 5-year LRRFS of 95.83% whereas patients with ypN\u2009+\u2009had 5-year LRRFS of 87.43% (<jats:italic>p<\/jats:italic>\u2009=\u20090.105). RNI was used in 16 ypN0 (48.5%) patients and 17 ypN+ (51.5%) patients. Patients treated with RNI had 5-year LRRFS of 93.4% as compared to 92.5% in the no RNI group (<jats:italic>p<\/jats:italic>\u2009=\u20090.868). Distant metastasis was detected in 5 patients (5%) with the most common sites being: liver, lung, bone, and CNS. Locoregional recurrence was significantly associated with distant failure (<jats:italic>p<\/jats:italic>\u2009=\u20090.002).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>cN\u2009+\u2009HER2\u2009+\u2009BC patients who achieve ypN0 after PST have excellent locoregional control. In contrast, patients with ypN\u2009+\u2009tend to have lower locoregional control. The utility of RNI in HER2\u2009+\u2009BC warrants further investigation.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/s12885-025-14289-4","type":"journal-article","created":{"date-parts":[[2025,6,4]],"date-time":"2025-06-04T09:14:30Z","timestamp":1749028470000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Radiation therapy in clinically node positive HER2 positive breast cancer after primary systemic therapy and breast conserving surgery: pooled analysis of TRYPHAENA and NeoSphere trials"],"prefix":"10.1186","volume":"25","author":[{"given":"Mohamad","family":"El-Jammal","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Omran","family":"Saifi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jose","family":"Bazan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Youssef H.","family":"Zeidan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,6,4]]},"reference":[{"issue":"4","key":"14289_CR1","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1093\/jnci\/djj052","volume":"98","author":"C Sotiriou","year":"2006","unstructured":"Sotiriou C, Wirapati P, Loi S, Harris A, Fox S, Smeds J, et al. Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis. J Natl Cancer Inst. 2006;98(4):262\u201372.","journal-title":"J Natl Cancer Inst"},{"issue":"8","key":"14289_CR2","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1016\/S1470-2045(21)00288-6","volume":"22","author":"Early Breast Cancer Trialists\u2019 Collaborative group (EBCTCG)","year":"2021","unstructured":"Early Breast Cancer Trialists\u2019 Collaborative group (EBCTCG). Trastuzumab for early-stage, HER2-positive breast cancer: a meta-analysis of 13\u2008864 women in seven randomised trials. Lancet Oncol. 2021;22(8):1139\u201350.","journal-title":"Lancet Oncol"},{"issue":"9712","key":"14289_CR3","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/S0140-6736(09)61964-4","volume":"375","author":"L Gianni","year":"2010","unstructured":"Gianni L, Eiermann W, Semiglazov V, Manikhas A, Lluch A, Tjulandin S, et al. Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort. Lancet. 2010;375(9712):377\u201384.","journal-title":"Lancet"},{"issue":"16","key":"14289_CR4","doi-asserted-by":"publisher","first-page":"3676","DOI":"10.1200\/JCO.2005.07.032","volume":"23","author":"AU Buzdar","year":"2005","unstructured":"Buzdar AU, Ibrahim NK, Francis D, Booser DJ, Thomas ES, Theriault RL, et al. Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer. J Clin Oncol. 2005;23(16):3676\u201385.","journal-title":"J Clin Oncol"},{"issue":"25","key":"14289_CR5","doi-asserted-by":"publisher","first-page":"3351","DOI":"10.1200\/JCO.2010.31.4930","volume":"29","author":"M Untch","year":"2011","unstructured":"Untch M, Fasching PA, Konecny GE, Hasm\u00fcller S, Lebeau A, Kreienberg R, et al. Pathologic complete response after neoadjuvant chemotherapy plus trastuzumab predicts favorable survival in human epidermal growth factor receptor 2-overexpressing breast cancer: results from the TECHNO trial of the AGO and GBG study groups. J Clin Oncol. 2011;29(25):3351\u20137.","journal-title":"J Clin Oncol"},{"issue":"9938","key":"14289_CR6","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/S0140-6736(13)62422-8","volume":"384","author":"P Cortazar","year":"2014","unstructured":"Cortazar P, Zhang L, Untch M, Mehta K, Costantino JP, Wolmark N, et al. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet. 2014;384(9938):164\u201372.","journal-title":"Lancet"},{"issue":"3","key":"14289_CR7","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1016\/j.ijrobp.2015.07.006","volume":"93","author":"YD Tseng","year":"2015","unstructured":"Tseng YD, Uno H, Hughes ME, Niland JC, Wong YN, Theriault R, et al. Biological subtype predicts risk of locoregional recurrence after mastectomy and impact of postmastectomy radiation in a large national database. Int J Radiat Oncol Biol Phys. 2015;93(3):622\u201330.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"14","key":"14289_CR8","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1056\/NEJM199710023371401","volume":"337","author":"M Overgaard","year":"1997","unstructured":"Overgaard M, Hansen PS, Overgaard J, Rose C, Andersson M, Bach F, et al. Postoperative radiotherapy in high-risk premenopausal women with breast cancer who receive adjuvant chemotherapy. Danish breast Cancer cooperative group 82b trial. N Engl J Med. 1997;337(14):949\u201355.","journal-title":"N Engl J Med"},{"issue":"9165","key":"14289_CR9","doi-asserted-by":"publisher","first-page":"1641","DOI":"10.1016\/S0140-6736(98)09201-0","volume":"353","author":"M Overgaard","year":"1999","unstructured":"Overgaard M, Jensen MB, Overgaard J, Hansen PS, Rose C, Andersson M, et al. Postoperative radiotherapy in high-risk postmenopausal breast-cancer patients given adjuvant tamoxifen: Danish Breast Cancer Cooperative Group DBCG 82c randomised trial. Lancet. 1999;353(9165):1641\u20138.","journal-title":"Lancet"},{"key":"14289_CR10","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.radonc.2022.03.008","volume":"170","author":"M Overgaard","year":"2022","unstructured":"Overgaard M, Nielsen HM, Tramm T, H\u00f8jris I, Grantzau TL, Alsner J, et al. Postmastectomy radiotherapy in high-risk breast cancer patients given adjuvant systemic therapy. A 30-year long-term report from the Danish breast cancer cooperative group DBCG 82bc trial. Radiother Oncol. 2022;170:4\u201313.","journal-title":"Radiother Oncol"},{"issue":"4","key":"14289_CR11","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1056\/NEJMoa1415369","volume":"373","author":"PM Poortmans","year":"2015","unstructured":"Poortmans PM, Collette S, Kirkove C, Van Limbergen E, Budach V, Struikmans H, et al. Internal mammary and medial supraclavicular irradiation in breast cancer. N Engl J Med. 2015;373(4):317\u201327.","journal-title":"N Engl J Med"},{"issue":"19","key":"14289_CR12","first-page":"1878","volume":"373","author":"TJ Whelan","year":"2015","unstructured":"Whelan TJ, Olivotto IA, Levine MN. Regional nodal irradiation in early-stage breast cancer. N Engl J Med. 2015;373(19):1878\u20139.","journal-title":"N Engl J Med"},{"issue":"10416","key":"14289_CR13","doi-asserted-by":"publisher","first-page":"1991","DOI":"10.1016\/S0140-6736(23)01082-6","volume":"402","author":"Early Breast Cancer Trialists\u2019 Collaborative Group (EBCTCG)","year":"2023","unstructured":"Early Breast Cancer Trialists\u2019 Collaborative Group (EBCTCG). Radiotherapy to regional nodes in early breast cancer: an individual patient data meta-analysis of 14 324 women in 16 trials. Lancet. 2023;402(10416):1991\u20132003.","journal-title":"Lancet"},{"issue":"S3","key":"14289_CR14","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1245\/s10434-015-4697-7","volume":"22","author":"TJ Yang","year":"2015","unstructured":"Yang TJ, Morrow M, Modi S, Zhang Z, Krause K, Siu C, et al. The effect of molecular subtype and residual disease on locoregional recurrence in breast cancer patients treated with neoadjuvant chemotherapy and postmastectomy radiation. Ann Surg Oncol. 2015;22(S3):495\u2013501.","journal-title":"Ann Surg Oncol"},{"key":"14289_CR15","doi-asserted-by":"publisher","first-page":"103594","DOI":"10.1016\/j.breast.2023.103594","volume":"72","author":"N Kim","year":"2023","unstructured":"Kim N, Kim JY, Park W, Cho WK, Kim TG, Im YH, et al. Benefit of postoperative regional nodal irradiation in patients receiving preoperative systemic therapy with docetaxel\/carboplatin\/trastuzumab\/pertuzumab for HER2-positive breast cancer. Breast. 2023;72:103594.","journal-title":"Breast"},{"issue":"9Supplement","key":"14289_CR16","first-page":"GS02","volume":"84","author":"E Mamounas","year":"2024","unstructured":"Mamounas E, Bandos H, White J, Julian T, Khan A, Shaitelman S, et al. Abstract GS02-07: loco-regional irradiation in patients with biopsy-proven axillary node involvement at presentation who become pathologically node-negative after neoadjuvant chemotherapy: primary outcomes of NRG oncology\/nsabp B-51\/RTOG 1304. Cancer Res. 2024;84(9Supplement):GS02\u201307.","journal-title":"Cancer Res"},{"issue":"9","key":"14289_CR17","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1016\/S1470-2045(22)00482-X","volume":"23","author":"SR de Wild","year":"2022","unstructured":"de Wild SR, de Munck L, Simons JM, Verloop J, van Dalen T, Elkhuizen PHM, et al. De-escalation of radiotherapy after primary chemotherapy in cT1-2N1 breast cancer (RAPCHEM; BOOG 2010-03): 5-year follow-up results of a Dutch, prospective, registry study. Lancet Oncol. 2022;23(9):1201\u201310.","journal-title":"Lancet Oncol"},{"key":"14289_CR18","doi-asserted-by":"publisher","first-page":"109668","DOI":"10.1016\/j.radonc.2023.109668","volume":"184","author":"O Saifi","year":"2023","unstructured":"Saifi O, Bachir B, Panoff J, Poortmans P, Zeidan YH. Post-mastectomy radiation therapy in HER-2 positive breast cancer after primary systemic therapy: pooled analysis of TRYPHAENA and neosphere trials. Radiother Oncol. 2023;184:109668.","journal-title":"Radiother Oncol"},{"issue":"1","key":"14289_CR19","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/S1470-2045(11)70336-9","volume":"13","author":"L Gianni","year":"2012","unstructured":"Gianni L, Pienkowski T, Im YH, Roman L, Tseng LM, Liu MC, et al. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial. Lancet Oncol. 2012;13(1):25\u201332.","journal-title":"Lancet Oncol"},{"issue":"9","key":"14289_CR20","doi-asserted-by":"publisher","first-page":"2278","DOI":"10.1093\/annonc\/mdt182","volume":"24","author":"A Schneeweiss","year":"2013","unstructured":"Schneeweiss A, Chia S, Hickish T, Harvey V, Eniu A, Hegg R, et al. Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA). Ann Oncol. 2013;24(9):2278\u201384.","journal-title":"Ann Oncol"},{"issue":"8","key":"14289_CR21","doi-asserted-by":"publisher","first-page":"djw331","DOI":"10.1093\/jnci\/djw331","volume":"109","author":"I Gingras","year":"2017","unstructured":"Gingras I, Holmes E, De Azambuja E, Nguyen DHA, Izquierdo M, Anne Zujewski J, et al. Regional nodal irradiation after breast conserving surgery for early HER2-positive breast cancer: results of a subanalysis from the ALTTO trial. J Natl Cancer Inst. 2017;109(8):djw331.","journal-title":"J Natl Cancer Inst"},{"issue":"4","key":"14289_CR22","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1097\/COC.0b013e31829d1eb8","volume":"38","author":"D Arsenault","year":"2015","unstructured":"Arsenault D, Hurley J, Takita C, Reis IM, Zhao W, Rodgers S, et al. Predictors of locoregional outcome in HER2-overexpressing breast cancer treated with neoadjuvant chemotherapy. Am J Clin Oncol. 2015;38(4):348\u201352.","journal-title":"Am J Clin Oncol"},{"issue":"32","key":"14289_CR23","doi-asserted-by":"publisher","first-page":"3960","DOI":"10.1200\/JCO.2011.40.8369","volume":"30","author":"EP Mamounas","year":"2012","unstructured":"Mamounas EP, Anderson SJ, Dignam JJ, Bear HD, Julian TB, Geyer CE, et al. Predictors of locoregional recurrence after neoadjuvant chemotherapy: results from combined analysis of national surgical adjuvant breast and bowel project B-18 and B-27. J Clin Oncol. 2012;30(32):3960\u20136.","journal-title":"J Clin Oncol"},{"issue":"4","key":"14289_CR24","doi-asserted-by":"publisher","first-page":"1030","DOI":"10.1016\/j.ijrobp.2020.06.028","volume":"108","author":"Z Huang","year":"2020","unstructured":"Huang Z, Zhu L, Huang XB, Tang Y, Rong QL, Shi M, et al. Postmastectomy radiation therapy based on pathologic nodal status in clinical node-positive stage II to III breast cancer treated with neoadjuvant chemotherapy. Int J Radiat Oncol Biol Phys. 2020;108(4):1030\u20139.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"3","key":"14289_CR25","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1016\/j.ijrobp.2022.03.007","volume":"113","author":"RB Mailhot Vega","year":"2022","unstructured":"Mailhot Vega RB, Wang S, Brooks ED, Oladeru OT, Lockney NA, Spiguel LE, et al. Evaluating regional nodal irradiation allocation and association with oncologic outcomes in NSABP B-18, B-27, B-40, and B-41. Int J Radiat Oncol Biol Phys. 2022;113(3):542\u201351.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1","key":"14289_CR26","doi-asserted-by":"publisher","first-page":"e35610","DOI":"10.1002\/cncr.35610","volume":"131","author":"M Muslumanoglu","year":"2025","unstructured":"Muslumanoglu M, Cabioglu N, Igci A, Karanl\u0131k H, Kocer HB, Senol K, et al. Combined analysis of the MF18-02\/MF18-03 NEOSENTITURK studies: ypN-positive disease does not necessitate axillary lymph node dissection in patients with breast cancer with a good response to neoadjuvant chemotherapy as long as radiotherapy is provided. Cancer. 2025;131(1):e35610.","journal-title":"Cancer"},{"issue":"7","key":"14289_CR27","doi-asserted-by":"publisher","first-page":"1565","DOI":"10.3390\/cancers13071565","volume":"13","author":"M Banys-Paluchowski","year":"2021","unstructured":"Banys-Paluchowski M, Gasparri ML, de Boniface J, Gentilini O, Stickeler E, Hartmann S, et al. Surgical management of the axilla in clinically node-positive breast cancer patients converting to clinical node negativity through neoadjuvant chemotherapy: current status, knowledge gaps, and rationale for the EUBREAST-03 AXSANA study. Cancers (Basel). 2021;13(7):1565.","journal-title":"Cancers (Basel)"},{"key":"14289_CR28","doi-asserted-by":"publisher","first-page":"1184021","DOI":"10.3389\/fonc.2023.1184021","volume":"13","author":"A Garcia-Tejedor","year":"2023","unstructured":"Garcia-Tejedor A, Ortega-Exposito C, Salinas S, Luzardo-Gonz\u00e1lez A, Falo C, Martinez-P\u00e9rez E, et al. Axillary lymph node dissection versus radiotherapy in breast cancer with positive sentinel nodes after neoadjuvant therapy (ADARNAT trial). Front Oncol. 2023;13:1184021.","journal-title":"Front Oncol"},{"issue":"10","key":"14289_CR29","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1001\/jama.2017.11470","volume":"318","author":"AE Giuliano","year":"2017","unstructured":"Giuliano AE, Ballman KV, McCall L, Beitsch PD, Brennan MB, Kelemen PR, et al. Effect of axillary dissection vs no axillary dissection on 10-year overall survival among women with invasive breast cancer and sentinel node metastasis: the ACOSOG Z0011 (Alliance) randomized clinical trial. JAMA. 2017;318(10):918\u201326.","journal-title":"JAMA"},{"key":"14289_CR30","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.breast.2021.09.004","volume":"60","author":"WP Weber","year":"2021","unstructured":"Weber WP, Matrai Z, Hayoz S, Tausch C, Henke G, Zwahlen DR, et al. Tailored axillary surgery in patients with clinically node-positive breast cancer: pre-planned feasibility substudy of TAXIS (OPBC-03, SAKK 23\/16, IBCSG 57\u201318, ABCSG-53, GBG 101). Breast. 2021;60:98\u2013110.","journal-title":"Breast"},{"issue":"7","key":"14289_CR31","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1007\/s00066-018-1270-x","volume":"194","author":"D Krug","year":"2018","unstructured":"Krug D, Baumann R, Budach W, Dunst J, Feyer P, Fietkau R, et al. Individualization of post-mastectomy radiotherapy and regional nodal irradiation based on treatment response after neoadjuvant chemotherapy for breast cancer: a systematic review. Strahlenther Onkol. 2018;194(7):607\u201318.","journal-title":"Strahlenther Onkol"},{"issue":"16suppl","key":"14289_CR32","doi-asserted-by":"publisher","first-page":"TPS615","DOI":"10.1200\/JCO.2022.40.16_suppl.TPS615","volume":"40","author":"A Goyal","year":"2022","unstructured":"Goyal A, Cramp S, Marshall A, Hammonds N, Wheatley D, Elsberger B, et al. ATNEC: a multicenter, randomized trial investigating whether axillary treatment can be avoided in patients with T1-3N1M0 breast cancer with no residual cancer in the lymph glands after neoadjuvant chemotherapy. JCO. 2022;40(16suppl):TPS615\u2013615.","journal-title":"JCO"},{"issue":"2","key":"14289_CR33","doi-asserted-by":"publisher","first-page":"100074","DOI":"10.1016\/j.esmoop.2021.100074","volume":"6","author":"J Delgado","year":"2021","unstructured":"Delgado J, Vleminckx C, Sarac S, Sosa A, Bergh J, Giuliani R, et al. The EMA review of trastuzumab emtansine (T-DM1) for the adjuvant treatment of adult patients with HER2-positive early breast cancer. ESMO Open. 2021;6(2):100074.","journal-title":"ESMO Open"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-025-14289-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-025-14289-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-025-14289-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,5]],"date-time":"2025-06-05T09:04:35Z","timestamp":1749114275000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-025-14289-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,4]]},"references-count":33,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["14289"],"URL":"https:\/\/doi.org\/10.1186\/s12885-025-14289-4","relation":{},"ISSN":["1471-2407"],"issn-type":[{"type":"electronic","value":"1471-2407"}],"subject":[],"published":{"date-parts":[[2025,6,4]]},"assertion":[{"value":"19 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 June 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable. Consents were initially collected as part of TRYPHAENA and NeoSphere Trials. This is a retrospective study on prospectively collected data approved by Vivli data agreement.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"996"}}